Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

REVEALED: William blair - The Real Truth

If You Lack Conviction in This Market, Here’s 1 Stock William Blair Thinks Deserves Your Attention

William Blair just added ORCL stock to its conviction list, with Oracle expected to be a major AI beneficiary.

Barchart

Black Rock Coffee Bar Targets 1,000 Stores as Loyalty Fuels Growth Plan

Black Rock Coffee Bar (NASDAQ:BRCB) executives outlined the company’s growth strategy, store economics and competitive positioning during a William Blair consumer event, emphasizing plans to sustain rapid unit expansion while leaning on customer loyalty, store-level execution and a differentiated ca

MarketBeat

BlackLine Says AI Agents, Platform Pricing Can Reignite Revenue Growth

BlackLine (NASDAQ:BL) executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session. Chair and CEO Owen Ryan described BlackLine as a “mission-

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

AeroVironment Sees Drone Demand Taking Off as Switchblade, Counter-Drone Capacity Expands

AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch

MarketBeat

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

MarketBeat

Align Technology Pitches AI-Powered Digital Dentistry Platform Beyond Invisalign

Align Technology (NASDAQ:ALGN) executives used a William Blair investor presentation to emphasize the company’s broader digital dentistry platform, positioning Invisalign as part of a workflow that spans consumer engagement, scanning, treatment planning, monitoring and retention. President and CEO

MarketBeat

Appian CFO Says AI Workflows, Government Demand Are Driving Big-Customer Growth

Appian (NASDAQ:APPN) Chief Financial Officer Serge Tanjga said the company is seeing stronger traction with large enterprise and government customers as it positions its low-code automation platform around regulated, mission-critical workflows and embedded artificial intelligence. Speaking at Willi

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Alkami Technology Touts $500M ARR, AI Upside and Bank Demand at Fintech Event

Alkami Technology (NASDAQ:ALKT) executives outlined the company’s growth strategy, financial outlook and market positioning during a William Blair fintech and payments event, emphasizing demand from regional banks and credit unions seeking digital capabilities comparable to large banks and fintechs.

MarketBeat

AAON Sees HVAC Recovery, $1B Data Center Opportunity Despite Margin Pressure

AAON (NASDAQ:AAON) executives outlined expectations for continued growth in both light commercial HVAC and data center markets during a William Blair presentation, while also addressing recent production challenges, margin pressure and ongoing efforts to scale the company’s operations. CEO Matt Tob

MarketBeat

Ignore the Amazon Trucking Noise and Buy UPS Stock for Its High Yield Near 7%

While Amazon’s logistics push is weighing on UPS stock, investors may want to consider the company’s shareholder-friendly approach before writing it off.

Barchart

Is Carvana Stock a Buy on New Stock Split Announcement?

Carvana stock inched up as the company announces 5-for-1 stock split. William Blair continues to recommend buying CVNA shares.

Barchart

Here’s What Options Traders Expect from Palantir Stock After Earnings

Palantir stock has slipped below $150 ahead of its earnings release on Feb. 2. But a William Blair analyst says the trajectory will reverse after the quarterly report later today.

Barchart

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

Benzinga

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.

Benzinga

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

Kezar Life Sciences, Inc. (NASDAQ:KZR) announced regulatory updates and began exploring strategic alternatives.

Benzinga

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

Benzinga

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Benzinga

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline

Dianthus Therapeutics Inc. (NASDAQ:DNTH) released topline data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG).

Benzinga

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ:ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Barchart

As Zero-Emission Credit Revenue Dries Up, What Does That Mean for Tesla Stock?

As Tesla loses its regulatory credit revenue stream, the company now faces growing pressure to sustain profitability through core operations amid cooling EV demand and intensifying competition.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.